Antibody & Phage Display

The Antibody & Phage Display Shared Resource provides a central site for the production of antibodies for cancer research. Its mission is to provide the resources and expertise to generate these reagents in a highly efficient and cost-effective manner. The Resource uses both phage display technology and classical hybridoma development protocols. The Phage Display branch of the Shared Resource provides the reagents and expertise to carry out the selection of Fabs (antibody fragments) against purified protein. This new technology is capable of rapidly producing high-affinity synthetic antibodies in a manner that complements existing expertise in classical hybridoma development and antibody production and purification. The Shared Resource maintains a library of all hybridomas generated, and will provide cell lines or antibody preparation from stored lines on request.

Explore all the CSHL Core Facilities

Shared Resource Staff

Resource Head

Adrian Krainer, Ph.D.


Johannes Yeh, Ph.D.


Carmelita Bautista

For phage display, the Resource has generated a Fab antibody fragment phage-display library comprising the heavy and light chain variable regions (VH-VL) and constant domains CH1-Ckappa of the heavy and light chains, respectively.  The Fab library contains a FLAG tag that can be used for downstream applications (Western blotting, IF, IP).

  • Phage Display Screens
  • Specificity/Affinity Optimization
  • Antibody Production

Researchers are also able to use this Resource to generate monoclonal antibodies. CSHL Cancer Center scientists provide specific antigens, and the Shared Resource personnel handle all stages of immunization, fusion, primary screening of hybridomas, cell culture, single-cell cloning, freezing and storage of hybridoma lines, and large-scale production of monoclonal antibodies in cell culture or in vivo. More details on the services are below:

  • Complete Hybridoma Development
    • Immunization
    • Cell Fusion
    • Screening
    • Cloning and amplification
  • Monoclonal Antibody Production (100 μg to 10 mg scale)
    • In vivo ascites
    • Cell culture supernatants
  • Isotyping
  • Storage and archiving of hybridoma lines
  • Polyclonal services are outsourced to Covance or to Primm

NCI logo
Cold Spring Harbor Laboratory is an NCI-designated Cancer Center. As a basic research institution, CSHL does not treat patients. Information about individual cancers is available at the NCI CancerNet. Questions about CSHL’s cancer research program should be directed to our Communications Department.